Skip to main content

Table 5 Klebsiella spp. isolatesa: adjusted estimates for resistance over time and by geographic region

From: A multicenter analysis of trends in resistance in urinary Enterobacterales isolates from ambulatory patients in the United States: 2011–2020

Characteristics

ESBL

Beta-lactam

Trimethoprim–sulfamethoxazole

Fluoroquinolones

Nitrofurantoin

Est (95% CI)

P

Est (95% CI)

P

Est (95% CI)

P

Est (95% CI)

P

Est (95% CI)

P

Year

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

 

< 0.001

 2011

6.3 (6.2–6.4)

 

92.8 (92.3–93.4)

 

11.0 (10.9–11.2)

 

6.7 (4.6–8.0)

 

58.5 (57.1–59.7)

 

 2012

6.4 (6.2–6.5)

 

91.4 (90.9–91.9)

 

10.4 (10.2–10.6)

 

6.9 (4.9–8.2)

 

60.0 (58.6–61.2)

 

 2013

6.4 (6.3–6.5)

 

89.5 (88.9–90.0)

 

9.9 (9.6–10.1)

 

6.9 (4.9–8.2)

 

60.8 (59.4–62.0)

 

 2014

6.6 (6.4–6.7)

 

87.7 (87.1–88.2)

 

9.3 (9.0–9.5)

 

5.6 (3.4–6.9)

 

59.8 (58.4–61.0)

 

 2015

6.6 (6.5–6.7)

 

86.8 (86.2–87.3)

 

10.5 (10.2–10.7)

 

6.2 (5.0–7.5)

 

57.2 (55.8–58.4)

 

 2016

6.6 (6.5–6.7)

 

85.8 (85.3–86.4)

 

10.4 (10.2–10.6)

 

5.9 (4.7–7.1)

 

52.5 (51.2–53.9)

 

 2017

6.7 (6.6–6.9)

 

84.9 (84.3–85.5)

 

10.3 (10.0–10.5)

 

5.9 (4.7–7.1)

 

53.4 (52.0–54.8)

 

 2018

6.8 (6.7–7.0)

 

84.0 (83.5–84.6)

 

10.6 (10.3–10.8)

 

6.0 (4.8–7.2)

 

54.7 (53.3–56.1)

 

 2019

6.9 (6.8–7.1)

 

82.8 (82.2–83.4)

 

11.4 (11.1–11.6)

 

6.3 (5.1–7.6)

 

55.4 (54.0–56.8)

 

 2020

7.2 (7.0–7.3)

 

81.1 (80.5–81.7)

 

11.3 (11.1–11.5)

 

6.8 (5.6–7.1)

 

59.2 (57.9–60.6)

 

Season (quarter)

 

0.336

 

0.038

 

0.310

 

0.060

 

 < 0.001

 1

6.9 (6.1–7.8)

 

86.1 (81.9–90.3)

 

10.8 (9.2–12.1)

 

6.5 (5.7–7.4)

 

55.8 (51.3–60.1)

 

 2

6.8 (6.0–7.7)

 

85.6 (81.1–89.8)

 

10.5 (9.0–11.9)

 

6.3 (5.4–7.1)

 

55.4 (50.6–59.7)

 

 3

6.7 (5.9–7.5)

 

85.1 (80.9–89.3)

 

10.4 (8.8–11.8)

 

6.1 (5.2–6.9)

 

57.2 (52.3–61.5)

 

 4

6.6 (5.8–7.4)

 

84.8 (80.3–89.0)

 

10.7 (9.1–12.2)

 

6.2 (5.3–7.1)

 

57.7 (53.0–62.0)

 

Census region

0.003

 

 < 0.001

 

0.050

 

 < 0.001

 

0.033

 East North Central

5.1 (4.1–6.0)

 

93.5 (88.8–98.2)

 

9.2 (7.3–10.6)

 

6.2 (5.2–7.2)

 

54.2 (48.5–59.6)

 

 East South Central

7.2 (6.2–8.3)

 

91.4 (86.3–96.2)

 

11.6 (10.0–13.0)

 

6.8 (5.7–7.8)

 

58.0 (52.3–62.7)

 

 Middle Atlantic

7.1 (6.1–8.1)

 

93.3 (88.6–98.0)

 

10.7 (9.0–12.2)

 

5.4 (4.3–6.4)

 

56.6 (50.9–61.9)

 

 Mountain

4.7 (3.8–5.7)

 

86.4 (81.7–91.2)

 

8.1 (6.6–9.5)

 

3.6 (2.9–4.6)

 

52.6 (46.9–57.8)

 

 New England

3.6 (3.0–4.2)

 

85.2 (82.3–88.1)

 

7.9 (7.1–8.8)

 

7.0 (5.9–8.1)

 

56.1 (52.0–61.3)

 

 Pacific

8.6 (7.6–9.6)

 

87.6 (82.9–92.3)

 

10.7 (8.8–12.1)

 

7.0 (5.9–8.0)

 

56.4 (50.7–61.8)

 

 South Atlantic

7.0 (6.0–7.9)

 

74.7 (70.0–79.5)

 

10.7 (8.9–12.0)

 

7.0 (5.9–8.0)

 

61.6 (56.0–67.1)

 

 West North Central

3.6 (2.9–4.3)

 

94.9 (91.9–97.7)

 

7.8 (6.3–9.0)

 

2.0 (1.1–3.0)

 

48.2 (43.9–53.4)

 

 West South Central

7.2 (6.2–8.1)

 

69.4 (64.6–74.1)

 

11.7 (9.7–13.3)

 

6.4 (5.3–7.5)

 

55.6 (50.0–61.1)

 
  1. CI confidence interval, ESBL extended-spectrum beta-lactamase-producing phenotype, Est estimated, NS not susceptible
  2. aK. pneumoniae, K. oxytoca, and K. aerogenes